Oppenheimer & Co’s Redhill Biopharma RDHL Stock Holding History

Oppenheimer & Co’s Portfolio RDHL Stock Details RDHL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-13	Closed	-$66K	–	1384
2017 Q4	$66K	Sell	13 -2	-13%	-$13.5K	﹤0.01%	1286
2017 Q3	$159K	Sell	15 -11	-42%	-$97.8K	﹤0.01%	1216
2017 Q2	$220K	Buy	26 +3	+13%	+$28.8K	0.01%	1137
2017 Q1	$221K	Buy	23 +6	+35%	+$59.9K	0.01%	1124
2016 Q4	$177K	Buy	17 +4	+31%	+$47.9K	0.01%	1176
2016 Q3	$180K	Hold	13	–	–	0.01%	1162
2016 Q2	$142K	Buy	+13	New	+$150K	﹤0.01%	1136

Other funds holding RDHL

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

CAM

Claret Asset Management Montreal, Quebec, Canada $837M AUM 25.51% 1-Year Est. Return

Oppenheimer & Co's RDHL Position: Q1 2018 in Review

Oppenheimer & Co sold out of Redhill Biopharma (RDHL) in Q1 2018, closing a stake of 13 shares — an estimated $66K sold.

Oppenheimer & Co first reported a position in RDHL in Q2 2016 and held it in 7 quarters. The position peaked at $221K in Q1 2017. 29 funds tracked by Wall St. Rank hold RDHL as of Q1 2018.

Oppenheimer & Co reported no remaining Redhill Biopharma position as of Q1 2018 after selling out during the quarter.
Oppenheimer & Co sold 13 Redhill Biopharma shares in Q1 2018, an estimated $66K.
Oppenheimer & Co first reported a position in Redhill Biopharma in Q2 2016 and held it in 7 quarters.
Oppenheimer & Co's Redhill Biopharma position peaked at $221K in Q1 2017.
29 funds tracked by Wall St. Rank held Redhill Biopharma as of Q1 2018.

Based on Oppenheimer & Co's 13F filing for Q1 2018, filed 1 May 2018.